Abstract
A chronic prostatic inflammation seems to play a crucial role in benign prostatic hyperplasia (BPH) pathogenesis and progression. Therefore, inflammation could represent a new potential target for medical therapy of lower urinary tract symptoms (LUTS) due to BPH (LUTS/BPH). This review article analyzes the evidence supporting the role of inflammation in the onset and progression of BPH, and it assesses the potential impact of previous mechanisms on medical therapy of LUTS/BPH. Literature data support the role of inflammation as a relevant factor in the pathogenesis of BPH. Indeed, several data favour the role of infiltrating lymphocytes in the development and progression of prostate adenoma as an effect of a self-maintaining remodeling process. Although available drugs commonly used in the treatment of LUTS/BPH do not exhibit an anti-inflammatory activity, it seems to be obvious considering the inflammation as a new target in the treatment of LUTS/BPH. Drugs currently investigated for the treatment of prostatic inflammation include the hexanic lipidosterolic extract of Serenoa repens, nonsteroidal anti-inflammatory drugs, and vitamin D receptor agonists.
Similar content being viewed by others
References
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Ribal MJ. The link between benign prostatic hyperplasia and inflammation. Eur Urol Suppl. 2013;12:103–9.
Sampson N, Untergasser G, Plas E, Berger P. The ageing male reproductive tract. J Pathol. 2007;211:206–18.
Nickel JC, Roehrborn CG, O’Leary MP, Bostwick DG, Somerville MC, Rittmaster RS. The relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol. 2008;54:1379–84.
De Nunzio C, Kramer G, Marberger M, et al. The controversial relationship between benign prostatic hyperplasia and prostate cancer: the role of inflammation. Eur Urol. 2011;60:106–17. This is a very comprehensive review article investigating the relationship between inflammation and benign prostatic hyperplasia. The article suggested that chronic prostatic inflammation may be involved in the development and progression of chronic prostatic disease, although there is still no evidence of a causal relation. Inflammation should be considered a new domain in basic and clinical research in patients with BPH.
Steiner GE, Newman ME, Paikl D, et al. Expression and function of proinflammatory interleukin IL-17 and IL-17 receptor in normal, benign hyperplastic, and malignant prostate. Prostate. 2003;56:171–82.
Steiner GE, Stix U, Handisurya A, et al. Cytokine expression pattern in benign prostatic hyperplasia infiltrating T cells and impact of lymphocytic infiltration on cytokine mRNA profile in prostatic tissue. Lab Invest. 2003;83:1131–46.
Ficarra V, Sekulovic S, Zattoni F, Zazzara M, Novara G. Why and how to evaluate chronic prostatic inflammation. Eur Urol Suppl. 2013;12:110–5. This review describes the recent literature regarding the relationship between prostatic inflammation and BPH and focuses on the clinical perspective of why and how to evaluate prostatic inflammation. The article highlighted the potential role of biomarkers, prostatic calcifications, symptoms severity, and metabolic syndrome to identify clinically patients with suspicious prostatic inflammation.
Ficarra V. Is chronic prostatic inflammation a new target in the medical therapy of lower urinary tract symptoms (LUTS) due to benign prostate hyperplasia (BPH)? BJU Int. 2013;112:421–2.
Gandaglia G, Briganti A, Gontero P, et al. The role of chronic prostatic inflammation in the pathogenesis and progression of benign prostatic hyperplasia (BPH). BJU Int. 2013;112:432–41. In this review article, the authors highlighted that although the histological examination of prostatic tissue remains the only available method to diagnose chronic inflammation, different parameters, such as prostatic calcifications, prostate volume, LUTS severity, storage and prostatitis-like symptoms, poor response to medical therapies, and urinary biomarkers, have been shown to be correlated with chronic inflammation.
Robert G, Descazeaud A, Allory Y, Vacherot F, de la Taille A. Should we investigate prostatic inflammation for the management of benign prostatic hyperplasia? Eur Urol Suppl. 2009;8:879–86.
De Nunzio C, Aronson W, Freedland SJ, Giovannucci E, Parsons JK. The correlation between metabolic syndrome and prostatic diseases. Eur Urol. 2012;61:560–70.
Oelke M, Bachmann A, Descazeaud A, et al. Guidelines on the management of male lower urinary tract symptoms (LUTS), incl. benign prostatic obstruction (BPO). Eur Assoc Urol. Web site http://www.uroweb.org.
Fullhase C, Chapple C, Cornu JN, et al. Systematic review of combination drug therapy for nonneurogenic male lower urinary tract symptoms. Eur Urol. 2013;64:228–43.
Madersbacher S, Marszalek M, Lackner J, et al. The long-term outcome of medical therapy for BPH. Eur Urol. 2007;51:1522–33.
Christ GJ, Andersson KE. Rho-kinase and effects of Rho-kinase inhibition on the lower urinary tract. Neurourol Urodyn. 2007;26:948–54.
Hennenberg M, Stief CG, Gratzke C. Prostatic α1-adrenoceptors: new concepts of function, regulation, and intracellular signaling. Neurourol Urodyn. 2014;33(7):1074–85.
Kwon YK, Choe MS, Seo KW, et al. The effect of intraprostatic chronic inflammation on benign prostatic hyperplasia treatment. Korean J Urol. 2010;51:266–70. This prospective clinical study showed that in patients with high-grade prostatic inflammation the use of alpha-blockers combined with 5-alpha-reductase inhibitors can be insufficient to reduce symptom severity, thus highlighting the need for alternative drugs.
de la Taille A. Therapeutic approach: the importance of controlling prostatic inflammation. Eur Urol Suppl. 2013;12:116–23. This review article examined the evidence for the role of inflammation in BPH and the use of various drug classes to reduce and prevent prostatic inflammation, with a particular focus on hexanic lipidosterolic extract of Serenoa repens (Permixon). Scientific evidence supports the conclusion that hexanic extract of Serenoa repens treats BPH through several mechanisms, one of which is reduction of inflammation.
Kahokehr A, Vather R, Nixon A, Hill AG. Non-steroidal anti-inflammatory drugs for lower urinary tract symptoms in benign prostatic hyperplasia: systematic review and meta-analysis of randomized controlled trials. BJU Int. 2013;111(2):304–11.
Colli E, Rigatti P, Montorsi F, et al. BXL628, a novel vitamin D3 analog arrests prostate growth in patients with benign prostatic hyperplasia: a randomized clinical trial. Eur Urol. 2006;49:82–6.
Cornu JN, Cussenot O, Haab F, Lukacs B. A widespread population study of actual medical management of lower urinary tract symptoms related to benign prostatic hyperplasia across Europe and beyond official clinical guidelines. Eur Urol. 2010;58:450–6.
Latil A, Libon C, Templier M, Junquero D, Lantoine-Adam F, Nguyen T. Hexanic lipidosterolic extract of Serenoa repens inhibits the expression of two key inflammatory mediators, MCP-1/CCL2 and VCAM-1, in vitro. BJU Int. 2012;110:301–7.
Vela Navarrete R, Garcia Cardoso JV, Barat A, Manzarbeitia F, López FA. BPH and inflammation: pharmacological effects of Permixon on histological and molecular inflammatory markers. Results of a double blind pilot clinical assay. Eur Urol. 2003;44:549–55.
Exploratory study of L.S.E.S.r. (lipidosterolic extract of Serenoa repens) (PERMIXON1 160 mg hard capsule) versus tamsulosine LP activity on inflammation biomarkers in the treatment of urinary symptoms related to BPH (benign prostatic hyperplasia) (PERMIN). NCT01604811. ClinicalTrials.gov Web site. http://clinicaltrials.gov/ct2/show/NCT01604811?term=serenoa+repens&rank=4.
Compliance with Ethics Guidelines
Conflict of Interest
Prof. Vincenzo Ficarra reports a grant and personal fees from Pierre Fabre.
Prof. Riccardo Bartoletti reports a grant and personal fees from Takeda Company and Pierre Fabre.
Dr. Marta Rossanese, Dr. Michele Zazzara, Dr. Gianluca Giannarini, Dr. Maria Abbinante, Prof. Vincenzo Mirone, and Dr. Francesco Scaglione each declare no potential conflicts of interest.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Author information
Authors and Affiliations
Corresponding author
Additional information
This article is part of the Topical Collection on Benign Prostatic Hyperplasia
Rights and permissions
About this article
Cite this article
Ficarra, V., Rossanese, M., Zazzara, M. et al. The Role of Inflammation in Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) and Its Potential Impact on Medical Therapy. Curr Urol Rep 15, 463 (2014). https://doi.org/10.1007/s11934-014-0463-9
Published:
DOI: https://doi.org/10.1007/s11934-014-0463-9